A legal fight between Novo Nordisk and Hims & Hers Health has quickly turned into a business partnership.

The drugmaker has agreed to dismiss its patent lawsuit after the two companies struck a deal to sell popular weight-loss medicines through the telehealth platform.

Under the agreement announced Monday, Hims & Hers will begin offering the branded medications Wegovy and Ozempic on its online platform later this month.

According to TheHill, the company will also stop promoting compounded or "copycat" versions of GLP-1 weight-loss drugs and instead shift to selling medicines approved by the US Food and Drug Administration.

The deal ends a dispute that escalated just weeks earlier. Last month, Hims & Hers said it planned to launch a cheaper, off-brand version of Wegovy, which contains the ingredient semaglutide.

Novo Nordisk strongly opposed the move and promised legal action, calling the product "an unapproved, inauthentic, and untested........

© International Business Times